IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) Lambda (C.37)

IBT Bioservices SARS-COV-2, Virus Like Particles (Ha-Cov2) Lambda (C.37) 

Summary

• SARS-CoV-2, Virus Like Particles (Ha-CoV2) Lambda (C.37) : hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV2) for strain Lambda (C.37) The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirusbased vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle. Formulation & Storage: Available upon request Store at -80°C. Notes & Usage Guidelines: Spike Mutations: Spike G75V, Spike T76I, Spike R246N, Spike del247/253, Spike L452Q, Spike F490S, Spike D614G, Spike T859N Size: 25 X 200 µL ~100 wells/96 well plate or 60x Conc. 5 x 100 µL Reporter: Available with Firefly luciferase, GFP, or RFP

Overview

Properties

• Form: Liquid
• Formulation: Available upon request
• Storage: -80°C
• Concentration: 1X Concentrated

MSE Supplies is an authorized distributor of IBT Bioservices products.